Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30720462 | 0.93 | OPRM1 (0.42) | OPRM1OPRD1OPRK1TASP1CTSB | |
| SCHEMBL29771973 | 0.92 | FOLH1 (0.44) | OPRM1OPRD1OPRK1TASP1CTSB | |
| SCHEMBL29772029 | 0.92 | OPRM1 (0.46) | OPRM1OPRD1OPRK1TASP1FOLH1 | |
| SCHEMBL30320500 | 0.91 | OPRM1 (0.43) | OPRM1OPRD1OPRK1NOD1FOLH1 | |
| SCHEMBL29772026 | 0.90 | FOLH1 (0.45) | OPRM1OPRD1OPRK1TASP1NOD1 | |
| SCHEMBL30844027 | 0.89 | OPRD1 (0.49) | OPRM1OPRD1OPRK1CTSBNOD1 | |
| SCHEMBL29493327 | 0.88 | OPRM1 (0.45) | OPRM1OPRD1OPRK1TASP1 | |
| SCHEMBL29360974 | 0.88 | OPRM1 (0.46) | OPRM1OPRD1OPRK1TASP1FOLH1 | |
| SCHEMBL31462107 | 0.88 | OPRM1 (0.45) | OPRM1OPRD1OPRK1TASP1 | |
| SCHEMBL30317594 | 0.88 | EGFR (0.44) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028388-A1 | RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE | SONOMA BIOTHERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| CN-119768508-A | Recombinant cytokine receptor and methods of use thereof | 索诺玛生物治疗公司 | 2025-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028388-A1 | RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE | IL2, IL2RA, IL23R | OPRM1 3388/4885OPRD1 1446/4885OPRK1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.